– FutureMeds leads the way: Europe’s first network of DCT sites generating momentum and results for clients and patients
With the goal of increasing DCT adoption, trial efficiencies and results, the company is on track to introduce a European DCT solution in September 2023.
LIVERPOOL, England, July 25, 2023 /PRNewswire/ — With the acquisition of emovis, the Berlin-based dedicated study site and award-winning pan-European provider of DCT solutions and home care visits, and by driving DCT readiness across the network, FutureMeds has become the first network of DCT sites in Europe.
Radoslaw Janiak, CEO of FutureMeds, said, “We are excited to generate significant momentum and results for our clients and patients. Accelerating the process of adapting DCT in the clinical trials industry in Europe can boost pharmaceutical RD productivity, support and influence go-to-market strategies, and significantly improve patient experience, engagement and outcomes.”
The emovis acquisition brings over 11 years of experience in delivering hybrid assays and a strong DCT framework, including the DEN Innovation Award-winning Homecare Visits (HCV) service. HCV is currently available in 16 EU countries and the UK, and is supported by a database of over 1,100 certified and clinical trial trained nurses.
“With high traditional and DCT readiness across the FutureMeds network, our established site infrastructure, emovis’ HomeCare visit service, and our combined expertise, we will be able to facilitate a more successful and efficient DCT implementation and test delivery,” said Iwona Tongbhoyai, Vice President of Operations at FutureMeds.
The company is now on track to introduce a European DCT solution in September that integrates the “voice of site and patient,” combines deep IP and site insights, novel trial design expertise, a home care solution, and operational excellence to drive clinical trial results and improve patient experience.
About FutureMeds
FutureMeds is an independent network of fast-growing, highly-ready DCT dedicated research sites that supports pharmaceutical companies, sponsors and CROs and contributes to research to find effective medicines and treatments for all patients who need them.
FutureMeds dedicated research site teams strive to accelerate study timelines, streamline processes, reduce costs and improve data quality to help speed patient access to new treatments.
About emovis
With more than 9,000 patients enrolled in more than 250 studies in 120 indications in 14 therapeutic areas, emovis has been a trusted and versatile service provider for Phase Ib-IV clinical trials since 2001.
In 2012, emovis launched the Home Care Visiting (HCV) service, which became one of the pillars of emovis’ current DCT offerings and framework.
Media contact:
Cameron Glen cameron.glen@futuremeds.com
Photo: https://mma.prnewswire.com/media/2158387…
View original content: https://www.prnewswire.com/news-releases/futuremeds-lidera-el-camino-301883934.html
